Therapeutic infusions of ketamine: Do the psychoactive effects matter?

Drug and Alcohol Dependence

Volumn 136, Issue 1, 2014, Pages 153-157

  Dakwar, E ^a,b   Anerella, C ^a   Hart, C L ^a,b,c   Levin, F R ^a,b   Mathew, S J ^d,e   Nunes, E V ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c Columbia University ^*  (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cocaine; Dependence; Ketamine; Mystical experience

Indexed keywords

COCAINE; DEPENDENCE; KETAMINE; MYSTICAL EXPERIENCE;

ADULT; ANESTHETICS, DISSOCIATIVE; COCAINE-RELATED DISORDERS; CRACK COCAINE; CUES; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISSOCIATIVE DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; INPATIENTS; KETAMINE; LORAZEPAM; MALE; MOTIVATION; MYSTICISM;

EID: 84893814571     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.12.019     Document Type: Article

References (32)

1. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:173-182.
2. Clements J.A., Nimmo W.S., Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharm. Sci. 1982, 71:539-542.
3. Dakwar E., Levin F.R., Foltin R.W., Nunes E.V., Hart C.L. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol. Psych. 2013, Sep 11, Epub ahead of print.
4. DiClemente C.C., Hughes S.O. Stages of change profiles in outpatient alcoholism treatment. J. Subst. Abuse 1990, 2:217-235.
5. Griffiths R.R., Richards W., Johnson M., McCann U., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008, 22:621-632.
6. Griffiths R.R., Richards W.A., McCann U., Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006, 187:268-283. discussion 284-292.
7. Hoffer A. Therapeutic uses. Psychedelics: The Uses and Implications of Hallucinogenic Drugs 1970, 357-366. Hogarth Press, London. B. Aaronson, H. Osmond (Eds.).
8. Hood R.W. The construction and preliminary validation of a measure of reported mystical experience. J. Sci. Study Relig. 1975, 14:29-41.
9. Hood R.W., Ghorbani N., Watson P.J., Ghramaleki A.F., Bing M.N., Davison H.K., Morris R.J., Williamson W.P. Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J. Sci. Study Relig. 2001, 40:691-705.
10. James W. The Varieties of Religious Experience: A Study in Human Nature 1907, Oxford World's Classics, Oxford.
11. Johnson M., Richards W., Griffiths R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 2008, 22:603-620.
12. Krupitsky E., Burakov A., Romanova T., Dunaevsky I., Strassman R., Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J. Subst. Abuse Treat. 2002, 23:273-283.
13. Krupitsky E., Grinenko A.Y. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J. Psychoactive Drugs 1997, 29:165-183.
14. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 20:959-964.
15. Lofwall M.R., Griffiths R.R., Mintzer M.Z. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp. Clin. Psychopharmacol. 2006, 14:439-449.
16. Maclean K.A., Leoutsakos J.M., Johnson M.W., Griffiths R.R. Factor analysis of the Mystical Experience Questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J. Sci. Study Relig. 2012, 51:721-737.
17. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
18. Mathew S.J., Shah A., Lapidus K., Clark C., Jarun N., Ostermeyer B., Murrough J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012, 26:189-204.
19. Miller W.R., C'de Baca J. Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives 2001, Guilford, New York, NY.
20. Miller W.R. The phenomenon of quantum change. J. Clin. Psychol. 2004, 5:453-460.
21. Perry E.B., Cramer J.A., Cho H.S., Petrakis I.L., Karper L.P., Genovese A., O'Donnell E., Krystal J.H., D'Souza D.C. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192:253-260.
22. Petrakis I.L., Limoncelli D., Gueorguieva R., Jatlow P., Boutros N.N., Trevisan L., Gelernter J., Krystal J.H. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am. J. Psychiatry 2004, 161:1776-1782.
23. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009, 66:522-526.
24. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A., Manji H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 2009, 65:289-295.
25. Scheidegger M., Walter M., Lehmann M., Metzger C., Grimm S., Boeker H., Boesiger P., Henning A., Seifritz E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One 2012, 7:e44799. 10.1371/journal.pone.0044799.
26. Siegal H.A., Li L., Rapp R.C., Saha P. Measuring readiness for change among crack cocaine users: a descriptive analysis. Subst. Use Misuse 2001, 36:687-700.
27. Skolnick P., Popik P., Trullas P. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009, 30:563-569.
28. Studerus E., Gamma A., Kometer M., Vollenweider F.X. Prediction of psilocybin response in healthy volunteers. PloS One 2012, 7:e30800.
29. Studerus E., Kometer M., Hasler F., Vollenweider F.X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 2011, 25:1434-1452.
30. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci. 2010, 11:642-651.
31. Wilson S.J., Sayette M.A., Fiez J.A. Prefrontal responses to drug cues: a neurocognitive analysis. Nat. Neurosci. 2004, 7:211-214.
32. Zarate C.A., Singh J.B., Carlson B.P., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant depression. Arch. Gen. Psychiatry 2006, 63:856-864.